Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT07908082

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07908082
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07908082. Randomized; quadruple masking; primary purpose prevention. Start 2027-10 (anticipated); primary completion 2030-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
Acronym
ASPIRE-GCA
Condition
Giant Cell Arteritis (GCA)
Condition
Acute Coronary Syndrome (ACS)
Condition
Ishemic and Thrombotic Complications
Intervention (Drug)
Acetyl Salicylic Acid (ASA)
Intervention (Drug)
Placebo
Lead sponsor
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal (class: other)

Record details

Record id
cardio:ct-nct07908082
Content hash
6506f52ae5e93218e4db98ff8b5c233dae5d10fb47ecc6c0bd9761fd45ab3ebd